Approach to the adult with interstitial lung disease: Diagnostic testing
- Talmadge E King, Jr, MD
Talmadge E King, Jr, MD
- Editor-in-Chief — Pulmonary and Critical Care Medicine
- Section Editor — Interstitial Lung Disease
- Dean, School of Medicine
- Vice Chancellor, Medical Affairs
- University of California San Francisco
The diffuse parenchymal lung diseases, often collectively referred to as the interstitial lung diseases (ILDs), are a heterogeneous group of disorders that are classified together because of similar clinical, radiographic, physiologic, or pathologic manifestations (algorithm 1) [1-5]. The descriptive term "interstitial" reflects the pathologic appearance that the abnormality begins in the interstitium, but the term is somewhat misleading, as most of these disorders are also associated with extensive alteration of alveolar and airway architecture.
The initial evaluation of patients with ILD is aimed at identifying the etiology of the ILD and its severity. The results of laboratory, radiographic, and pulmonary function tests guide the decisions about whether to pursue bronchoalveolar lavage and/or transbronchoscopic, thoracoscopic, or open lung biopsy.
An overview of the diagnostic testing that is helpful in the diagnosis of ILD will be presented here (algorithm 2) [6-8]. The clinical findings that aid in the diagnosis of ILD and the individual causes of ILD are discussed separately. (See "Approach to the adult with interstitial lung disease: Clinical evaluation" and "Idiopathic interstitial pneumonias: Clinical manifestations and pathology" and "Clinical manifestations and diagnosis of pulmonary sarcoidosis" and "Role of bronchoalveolar lavage in diagnosis of interstitial lung disease" and "Pulmonary toxicity associated with systemic antineoplastic therapy: Clinical presentation, diagnosis, and treatment".)
CAUSES OF ILD
The list of causes of interstitial lung disease (ILD), also known as diffuse parenchymal lung disease, is broad and includes those ILDs that are associated with a broad range of diseases (table 1), exposures (table 2A-B), and drugs (table 3). ILD may also occur as an idiopathic condition (algorithm 1). The treatment choices and prognosis vary among the different causes and types of ILD, so ascertaining the correct diagnosis is important.
A variety of infectious processes cause interstitial opacities on chest radiograph, including fungal pneumonias (eg, coccidioidomycosis, cryptococcosis, Pneumocystis jirovecii), atypical bacterial pneumonias, and viral pneumonias. These infections often occur in immunocompromised hosts and are discussed separately. (See "Approach to the immunocompromised patient with fever and pulmonary infiltrates".)To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information on subscription options, click below on the option that best describes you:
- Bradley B, Branley HM, Egan JJ, et al. Interstitial lung disease guideline: the British Thoracic Society in collaboration with the Thoracic Society of Australia and New Zealand and the Irish Thoracic Society. Thorax 2008; 63 Suppl 5:v1.
- Mittoo S, Gelber AC, Christopher-Stine L, et al. Ascertainment of collagen vascular disease in patients presenting with interstitial lung disease. Respir Med 2009; 103:1152.
- Tillie-Leblond I, Wislez M, Valeyre D, et al. Interstitial lung disease and anti-Jo-1 antibodies: difference between acute and gradual onset. Thorax 2008; 63:53.
- Kobayashi J, Kitamura S. KL-6: a serum marker for interstitial pneumonia. Chest 1995; 108:311.
- Travis WD, Costabel U, Hansell DM, et al. An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 2013; 188:733.
- Ohnishi H, Yokoyama A, Kondo K, et al. Comparative study of KL-6, surfactant protein-A, surfactant protein-D, and monocyte chemoattractant protein-1 as serum markers for interstitial lung diseases. Am J Respir Crit Care Med 2002; 165:378.
- Nakajima H, Harigai M, Hara M, et al. KL-6 as a novel serum marker for interstitial pneumonia associated with collagen diseases. J Rheumatol 2000; 27:1164.
- Pipavath S, Godwin JD. Imaging of interstitial lung disease. Clin Chest Med 2004; 25:455.
- Kinder BW, Collard HR, Koth L, et al. Idiopathic nonspecific interstitial pneumonia: lung manifestation of undifferentiated connective tissue disease? Am J Respir Crit Care Med 2007; 176:691.
- Corte TJ, Copley SJ, Desai SR, et al. Significance of connective tissue disease features in idiopathic interstitial pneumonia. Eur Respir J 2012; 39:661.
- Kim HC, Ji W, Kim MY, et al. Interstitial pneumonia related to undifferentiated connective tissue disease: pathologic pattern and prognosis. Chest 2015; 147:165.
- Kinder BW, Brown KK, McCormack FX, et al. Serum surfactant protein-A is a strong predictor of early mortality in idiopathic pulmonary fibrosis. Chest 2009; 135:1557.
- Al-Salmi QA, Walter JN, Colasurdo GN, et al. Serum KL-6 and surfactant proteins A and D in pediatric interstitial lung disease. Chest 2005; 127:403.
- Aziz ZA, Wells AU, Hansell DM, et al. HRCT diagnosis of diffuse parenchymal lung disease: inter-observer variation. Thorax 2004; 59:506.
- Wells A. Clinical usefulness of high resolution computed tomography in cryptogenic fibrosing alveolitis. Thorax 1998; 53:1080.
- Johkoh T, Müller NL, Cartier Y, et al. Idiopathic interstitial pneumonias: diagnostic accuracy of thin-section CT in 129 patients. Radiology 1999; 211:555.
- Wittram C, Mark EJ, McLoud TC. CT-histologic correlation of the ATS/ERS 2002 classification of idiopathic interstitial pneumonias. Radiographics 2003; 23:1057.
- Lynch DA, Travis WD, Müller NL, et al. Idiopathic interstitial pneumonias: CT features. Radiology 2005; 236:10.
- Elliot TL, Lynch DA, Newell JD Jr, et al. High-resolution computed tomography features of nonspecific interstitial pneumonia and usual interstitial pneumonia. J Comput Assist Tomogr 2005; 29:339.
- Sumikawa H, Johkoh T, Ichikado K, et al. Usual interstitial pneumonia and chronic idiopathic interstitial pneumonia: analysis of CT appearance in 92 patients. Radiology 2006; 241:258.
- Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011; 183:788.
- Wells AU. The revised ATS/ERS/JRS/ALAT diagnostic criteria for idiopathic pulmonary fibrosis (IPF)--practical implications. Respir Res 2013; 14 Suppl 1:S2.
- Floudas CS, Kanakis MA, Andreopoulos A, Vaiopoulos GA. Nodular lung calcifications following varicella zoster virus pneumonia. QJM 2008; 101:159.
- Prakash P, Kalra MK, Sharma A, et al. FDG PET/CT in assessment of pulmonary lymphangitic carcinomatosis. AJR Am J Roentgenol 2010; 194:231.
- Martinez FJ, Flaherty K. Pulmonary function testing in idiopathic interstitial pneumonias. Proc Am Thorac Soc 2006; 3:315.
- Caminati A, Harari S. Which prognostic indicator should we use for clinical practice in the initial evaluation and follow-up of IIP: should we depend on PFT, HRCT or...what? Sarcoidosis Vasc Diffuse Lung Dis 2005; 22 Suppl 1:S24.
- Lama VN, Martinez FJ. Resting and exercise physiology in interstitial lung diseases. Clin Chest Med 2004; 25:435.
- Chetta A, Marangio E, Olivieri D. Pulmonary function testing in interstitial lung diseases. Respiration 2004; 71:209.
- Latsi PI, du Bois RM, Nicholson AG, et al. Fibrotic idiopathic interstitial pneumonia: the prognostic value of longitudinal functional trends. Am J Respir Crit Care Med 2003; 168:531.
- Hallstrand TS, Boitano LJ, Johnson WC, et al. The timed walk test as a measure of severity and survival in idiopathic pulmonary fibrosis. Eur Respir J 2005; 25:96.
- Flaherty KR, Andrei AC, Murray S, et al. Idiopathic pulmonary fibrosis: prognostic value of changes in physiology and six-minute-walk test. Am J Respir Crit Care Med 2006; 174:803.
- Lama VN, Flaherty KR, Toews GB, et al. Prognostic value of desaturation during a 6-minute walk test in idiopathic interstitial pneumonia. Am J Respir Crit Care Med 2003; 168:1084.
- Eaton T, Young P, Milne D, Wells AU. Six-minute walk, maximal exercise tests: reproducibility in fibrotic interstitial pneumonia. Am J Respir Crit Care Med 2005; 171:1150.
- Swigris JJ, Swick J, Wamboldt FS, et al. Heart rate recovery after 6-min walk test predicts survival in patients with idiopathic pulmonary fibrosis. Chest 2009; 136:841.
- Swigris JJ, Olson AL, Shlobin OA, et al. Heart rate recovery after six-minute walk test predicts pulmonary hypertension in patients with idiopathic pulmonary fibrosis. Respirology 2011; 16:439.
- Taleb M, Khuder S, Tinkel J, Khouri SJ. The diagnostic accuracy of Doppler echocardiography in assessment of pulmonary artery systolic pressure: a meta-analysis. Echocardiography 2013; 30:258.
- Finkelhor RS, Lewis SA, Pillai D. Limitations and strengths of doppler/echo pulmonary artery systolic pressure-right heart catheterization correlations: a systematic literature review. Echocardiography 2015; 32:10.
- Costabel U, Guzman J. Bronchoalveolar lavage. In: Interstitial Lung Disease, 4th ed, King TE Jr, Schwarz MI (Eds), B.C. Decker, Hamilton, ON, Canada 2003. p.114.
- Kinder BW, Wells AU. The art and science of diagnosing interstitial lung diseases. Am J Respir Crit Care Med 2009; 179:974.
- Ohshimo S, Bonella F, Cui A, et al. Significance of bronchoalveolar lavage for the diagnosis of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2009; 179:1043.
- Raghu G. Interstitial lung disease: a diagnostic approach. Are CT scan and lung biopsy indicated in every patient? Am J Respir Crit Care Med 1995; 151:909.
- CAUSES OF ILD
- CLINICAL EVALUATION
- LABORATORY TESTS
- Chest radiography
- Computed tomography
- Other imaging
- PULMONARY FUNCTION TESTING
- Spirometry and lung volumes
- Diffusing capacity
- Gas exchange at rest and on exertion
- CARDIAC EVALUATION
- ROLE OF BRONCHOALVEOLAR LAVAGE
- ROLE OF LUNG BIOPSY
- INFORMATION FOR PATIENTS
- SUMMARY AND RECOMMENDATIONS